Insider Trading Activity Regulus Therapeutics Inc. (NASDAQ:RGLS) – Insider Bought 219,780 shares of Stock

ME Staff
-
0

Insider Trading Activity For Regulus Therapeutics Inc. (NASDAQ:RGLS)

Joseph P Hagan , Insider of Regulus Therapeutics Inc. (NASDAQ:RGLS) reportedly Bought 219,780 shares of the company’s stock at an average price of 0.91 for a total transaction amount of $199,999.80 SEC Form

Insider Trading History For Regulus Therapeutics Inc. (NASDAQ:RGLS)

  • On 10/10/2012 Stanley T Crooke, Director, bought 750,000 with an average share price of $4.00 per share and the total transaction amounting to $3,000,000.00.View SEC Filing
  • On 1/2/2014 Kleanthis Xanthopoulos, CEO, sold 3,505 with an average share price of $7.25 per share and the total transaction amounting to $25,411.25.View SEC Filing
  • On 1/16/2014 Neil Gibson, Insider, sold 1,100 with an average share price of $8.03 per share and the total transaction amounting to $8,833.00.View SEC Filing
  • On 1/17/2014 Neil Gibson, Insider, sold 4,479 with an average share price of $8.15 per share and the total transaction amounting to $36,503.85.View SEC Filing
  • On 1/21/2014 Neil Gibson, Insider, sold 4,421 with an average share price of $8.09 per share and the total transaction amounting to $35,765.89.View SEC Filing
  • On 2/4/2014 Sanofi, major shareholder, bought 1,303,780 with an average share price of $7.67 per share and the total transaction amounting to $9,999,992.60.View SEC Filing
  • On 7/9/2014 Isis Pharmaceuticals Inc, Director, sold 1,800 with an average share price of $7.08 per share and the total transaction amounting to $12,744.00.View SEC Filing

    • Analyst Ratings For Regulus Therapeutics Inc. (NASDAQ:RGLS)
    These are 4 Hold Ratings, 2 Buy Ratings .
    The current consensus rating for Regulus Therapeutics Inc. (NASDAQ:RGLS) is Hold (Score: 2.33) with a consensus target price of $4.50 , a potential (305.41% upside)

    Analyst Ratings History For Regulus Therapeutics Inc. (NASDAQ:RGLS)

    • On 6/28/2016 FBR & Co Reiterated Rating Outperform with a price target of $30.00 to $9.00
    • On 1/30/2017 Wells Fargo & Company Downgraded rating Outperform to Market Perform
    • On 1/30/2017 Needham & Company LLC Downgraded rating Buy to Hold
    • On 3/3/2017 Cantor Fitzgerald Lower Price Target of rating Buy with a price target of $7.00 to $4.00
    • On 3/3/2017 Cowen and Company Reiterated Rating Hold
    • On 6/13/2017 Chardan Capital Lower Price Target of rating Buy to Buy with a price target of $5.00 to $2.50
    • On 6/13/2017 Wedbush Reiterated Rating Ourperform with a price target of $6.00

    Recent Trading Activity for Regulus Therapeutics Inc. (NASDAQ:RGLS)
    Shares of Regulus Therapeutics Inc. closed the previous trading session at 1.11 up +0.01 0.91% with 1,144,916 shares trading hands.